Longevity medicine is an emerging clinical field built on a single organizing idea: aging itself is a treatable biological process, not just an inevitable backdrop to disease. Rather than waiting for heart disease, cancer, or dementia to appear and treating each one separately, longevity medicine aims to slow or reverse the underlying biology that makes all of them more likely as we get older. The concept rests on what researchers call the geroscience hypothesis, which holds that the mechanisms driving aging simultaneously drive multiple chronic illnesses, and that intervening in those mechanisms can prevent or delay many diseases at once.1PubMed Central. HEALTHY AGING: THE PROMISE, AND PERILS, OF GEROSCIENCE The field pulls together pharmacology, molecular biology, nutrition science, and diagnostic technology into a single practice focused on extending not just how long you live, but how long you live well.
Healthspan, Not Just Lifespan
The distinction between lifespan and healthspan is central to everything longevity medicine does. Lifespan is total years alive. Healthspan is the portion of those years spent free of serious disease and disability. In many developed countries, average lifespan has increased dramatically over the past century, but the final years are often marked by chronic illness, frailty, and declining independence. The goal of longevity medicine is to compress that period of decline, pushing it closer to the end of life so that more of your years are healthy ones.2PubMed Central. Lifespan and Healthspan: Past, Present, and Promise
This reframing matters because it changes what counts as success. A drug that adds two years to your life but leaves you bedridden for five is a failure by healthspan standards. A drug that adds zero years but keeps you physically and cognitively functional until the final months is a win. Most of the interventions being studied in longevity medicine are evaluated with this lens, even when the headline metric in a given study is survival time.
The Hallmarks of Aging
To treat aging, you need a map of what aging actually is at the cellular level. The most influential framework in the field was published in 2013, identifying nine biological hallmarks that appear to be common denominators of aging across species. These include things like genomic instability (accumulated DNA damage), telomere shortening, epigenetic drift (changes in how genes are switched on and off), the buildup of misfolded proteins, mitochondrial dysfunction, and cellular senescence, where damaged cells stop dividing but refuse to die and instead leak inflammatory signals into surrounding tissue.3PubMed Central. The hallmarks of aging
The list was updated in 2023 to twelve hallmarks, adding chronic inflammation, disrupted autophagy (the cell’s waste-recycling system), and dysbiosis, which refers to harmful shifts in the gut microbiome.4PubMed. Hallmarks of aging: An expanding universe These hallmarks are deeply interconnected. Mitochondrial dysfunction feeds inflammation. Inflammation accelerates senescent cell accumulation. Senescent cells impair stem cell function. Longevity medicine treats this web as a set of druggable targets, and most of the interventions being studied hit more than one hallmark simultaneously.
Measuring Biological Age
One of the practical challenges of treating aging is knowing whether your treatment is working. You cannot wait decades to see if someone lives longer. This has driven intense interest in biomarkers that estimate biological age, the idea being that your body’s internal wear and tear may not match your passport age. A 55-year-old with the cardiovascular system, immune profile, and cellular repair capacity of a typical 45-year-old would have a younger biological age.
The most studied tool for this is the epigenetic clock. It works by reading chemical tags called methylation marks on DNA. Researchers have identified specific sets of methylation sites whose collective pattern closely tracks chronological age, and deviations from the expected pattern can indicate whether someone is aging faster or slower than average.5PubMed Central. DNA Methylation Clocks in Aging: Categories, Causes, and Consequences These clocks are not just academic curiosities. A meta-analysis found that accelerated epigenetic age, meaning a biological age reading higher than your actual age, independently predicted earlier death across multiple racial and ethnic groups, even after adjusting for conventional risk factors like smoking and blood pressure.6PubMed Central. DNA methylation-based measures of biological age: meta-analysis predicting time to death
Epigenetic clocks are now used in longevity research as a surrogate endpoint, a way to test whether an intervention is actually slowing biological aging on a timeline shorter than a full human lifetime. They are also being tested as potential tools for rejuvenation studies, where researchers want to know if a given treatment can dial back a cell’s epigenetic age.7PubMed Central. DNA methylation aging clocks: challenges and recommendations That said, the field is still debating how well these clocks capture the full picture of aging versus just one dimension of it.
Beyond epigenetic clocks, researchers are building multi-layered diagnostic profiles. One approach uses metabolic markers from large population databases to construct aging scores that correlate with established aging indicators and can predict short-term mortality risk.8PubMed Central. Towards Precision Aging Biology: Single-Cell Multi-Omics and Advanced AI-Driven Strategies The eventual vision is a dashboard of biological age readouts drawn from blood, DNA methylation, the microbiome, and metabolic panels, giving clinicians a granular picture of which systems are aging fastest in a given patient.
Drug Candidates Targeting Aging
No drug is currently approved by regulatory agencies for the treatment of aging itself, but several candidates are in active study. The most prominent fall into a few categories.
Rapamycin and mTOR Inhibition
Rapamycin is an immunosuppressant drug already approved for organ transplant patients. It works by inhibiting a protein called mTOR, which acts as a master switch for cell growth and nutrient sensing. When mTOR is dialed down, cells shift from growth mode into maintenance and repair mode, ramping up autophagy and improving protein quality control. In animal studies, rapamycin has extended lifespan and improved health across mice, worms, flies, and yeast.9PubMed Central. Targeting the biology of aging with mTOR inhibitors The mTOR pathway connects to several hallmarks of aging at once, including nutrient sensing, autophagy, mitochondrial function, cellular senescence, and stem cell decline.10PubMed Central. mTOR as a central regulator of lifespan and aging
In humans, rapamycin’s use as a longevity drug is still experimental. At the high doses used for transplant patients, it suppresses the immune system enough to cause real problems. Researchers are exploring whether much lower doses, or intermittent dosing schedules, can deliver anti-aging benefits without meaningful immune suppression. Some longevity clinicians already prescribe it off-label, which is controversial because the human evidence for this specific application is thin.
Metformin
Metformin is the world’s most widely prescribed diabetes drug, and it has attracted longevity researchers’ attention because of observational data suggesting diabetic patients on metformin sometimes outlive matched non-diabetic controls. Its anti-aging mechanisms appear to overlap with several hallmarks, including activation of a cellular energy sensor called AMPK, inhibition of the same mTOR pathway that rapamycin targets, reduction of oxidative stress, and dampening of chronic low-grade inflammation.11PubMed Central. Molecular mechanisms of metformin action: From metabolic effects to lifespan extension and healthspan promotion
The big test is the TAME trial (Targeting Aging with Metformin), which is notable not just for studying metformin but for being the first clinical trial the FDA has accepted that treats aging as a composite multi-disease outcome rather than a single condition.12PubMed Central. Beyond disease treatment and prevention: From geroscience and molecular hallmarks to gerotherapeutics and precision geromedicine If it succeeds, the trial could establish a regulatory template for future aging-targeted drugs.
Senolytics
Senescent cells are sometimes called “zombie cells” in popular coverage, and the nickname is surprisingly apt. They are damaged cells that stop dividing but do not die. Instead, they accumulate with age and secrete a cocktail of inflammatory molecules that damage neighboring healthy tissue. Senolytic drugs are designed to selectively kill these cells. In animal models, clearing senescent cells improves physical function, reduces inflammation, and extends healthy lifespan. Several senolytic drug candidates are now in early-stage human trials for conditions ranging from osteoarthritis to pulmonary fibrosis.13PubMed Central. Cellular senescence and senolytics: the path to the clinic
NAD+ Boosters
NAD+ is a molecule every cell uses to convert food into energy and to activate repair enzymes called sirtuins. Levels of NAD+ decline with age across multiple tissues, and this decline tracks with many of the functional losses associated with getting older.14PubMed Central. NAD+ biosynthesis, aging, and disease The logic behind NAD+ supplementation is straightforward: if declining NAD+ contributes to aging, then restoring it might slow or reverse age-related damage. In animal studies, supplementation with NAD+ precursors like NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) has shown real promise. Long-term NMN administration in aged mice improved mitochondrial function in skeletal muscle, enhanced insulin sensitivity, improved bone density, and reversed age-associated gene expression changes.15PubMed Central. NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health – Section: Anti-Aging Effect
Early human trials of NMN and NR have generally confirmed that these supplements raise blood NAD+ levels safely. What remains unclear is whether that translates into meaningful anti-aging effects in people. Animal models of aging do not always predict human outcomes well, and the supplement industry has raced far ahead of the clinical evidence, with NMN and NR already sold widely as consumer products. The combination of sirtuin activation and NAD+ restoration remains one of the more promising theoretical strategies, but the human data is still catching up to the enthusiasm.16PubMed Central. NAD+ and sirtuins in aging and disease
Cellular Reprogramming
Perhaps the most sci-fi-sounding area of longevity research is partial cellular reprogramming. The basic idea comes from the discovery that adult cells can be returned to an embryonic-like state by activating a set of genes known as Yamanaka factors. Full reprogramming converts a skin cell into a stem cell, erasing its identity entirely. Partial reprogramming aims to do something more subtle: dial back the epigenetic age of a cell without stripping away its specialized function.17PubMed Central. Partial cellular reprogramming: A deep dive into an emerging rejuvenation technology
The challenge is obvious and significant: push reprogramming too far, and you get uncontrolled cell growth (essentially cancer). Stop too early, and you may not get meaningful rejuvenation. Researchers are working on precise timing and delivery methods to thread this needle. In one study, gene therapy delivering partial reprogramming factors to aged mice extended their lifespan and reversed age-related changes, while experiments in human skin cells showed epigenetic markers shifting toward a younger state.18PubMed Central. Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice Chemical cocktails that mimic the effects of Yamanaka factors without requiring gene therapy are also under investigation, since a pill would be far easier to deliver than a viral vector.19Nature Communications. The long and winding road of reprogramming-induced rejuvenation This area has attracted enormous commercial investment, but clinical applications in humans remain years away.
Diet, Caloric Restriction, and Nutrient Sensing
Before any drug entered the picture, caloric restriction was the most reliable way to extend lifespan in laboratory animals. Reducing calorie intake without malnutrition has extended life in yeast, worms, flies, and rodents, and the effect appears to work through the same nutrient-sensing pathways that drugs like rapamycin and metformin target.20PubMed Central. Calorie restriction and the nutrient sensing signaling pathways When calories are scarce, cells shift resources away from growth and reproduction toward repair and stress resistance. This triggers a cascade of protective responses, including improved mitochondrial function, enhanced autophagy, and reduced inflammation.21PubMed. Mitochondrial function and nutrient sensing pathways in ageing: enhancing longevity through dietary interventions
For humans, long-term severe caloric restriction is impractical and brings its own risks, including muscle loss, immune suppression, and reduced bone density. This is exactly why pharmacological mimics of caloric restriction are so appealing. The nutrient-sensing pathways that caloric restriction activates become less responsive with age, which is itself one of the hallmarks of aging.22PubMed Central. NutrimiRAging: Micromanaging Nutrient Sensing Pathways through Nutrition to Promote Healthy Aging Intermittent fasting and time-restricted eating are less extreme dietary strategies that appear to activate some of the same pathways, though the human evidence for lifespan effects is limited to short-term metabolic improvements rather than long-term survival data.
The Gut Microbiome and Aging
The addition of dysbiosis to the updated hallmarks list reflects growing evidence that the gut microbiome plays an active role in aging rather than simply changing as a byproduct of it. Observational studies in humans find stark differences between the microbiomes of long-lived individuals and those of frail older adults, though it remains difficult to determine cause and effect.23Cell Host & Microbe. The Gut Microbiome as a Target for Aging and Frailty In animal models, the picture is somewhat clearer: age-related shifts in microbial communities contribute to increased intestinal permeability (often called “leaky gut”), which allows bacterial products to enter the bloodstream and fuel chronic, low-grade systemic inflammation.
This inflammation feeds into a broader cycle. Chronic immune stimulation from gut-derived signals contributes to the age-related decline in immune function, which in turn leads to higher infection risk and poorer responses to vaccines.24Genes & Immunity. The aging gut microbiome and its impact on host immunity Interventions targeting the microbiome, whether through diet, probiotics, or eventually more precise microbial therapies, are being explored as a way to break this cycle. The challenge is that the microbiome is extraordinarily complex and variable between individuals, making it difficult to define what a “young” or “healthy” microbiome looks like in universal terms.
Young Blood and Circulating Factors
Some of the most striking results in aging research come from experiments that sound like they belong in a gothic novel. Heterochronic parabiosis, in which a young animal and an old animal are surgically joined so they share a blood supply, has shown that factors in young blood can reverse age-related damage in older animals across the brain, muscle, liver, heart, and vasculature.25PubMed Central. Plasma-based strategies for systemic rejuvenation: critical perspectives on clinical translation The reverse is also true: old blood impairs tissue function in young partners, suggesting that aging is regulated in part by circulating molecular signals rather than being locked into each tissue independently.
At the cellular level, older animals exposed to young circulation showed reduced senescent cells in multiple organs, less inflammation and fibrosis in the liver, and restored muscle fiber size and hair follicle density.26Cell Stem Cell. A single-cell transcriptomic atlas characterizing aging rejuvenation in heterochronic parabiosis Young blood transfer has also been shown to induce broad transcriptomic, metabolic, and epigenetic rejuvenation across multiple tissues.27PubMed Central. Blood as the mirror and modulator of aging: mechanistic insights and rejuvenation strategies
The practical question is whether these results can translate into human therapies. Simply transfusing young plasma into older people is not a scalable or well-supported approach, and early commercial ventures offering “young blood transfusions” were widely criticized by the research community. The real value of the parabiosis experiments is in identifying the specific molecules responsible for the rejuvenating effects so that those can be synthesized and tested as drugs. That work is underway, but identifying which of the thousands of circulating factors matter most is slow going.
Mitochondrial Health and Urolithin A
Mitochondrial dysfunction is one of the original hallmarks, and it connects to nearly every other aging process. As mitochondria degrade with age, cells produce less energy and more damaging byproducts. One emerging intervention targets mitophagy, the process by which cells recycle damaged mitochondria. Urolithin A, a compound produced by gut bacteria from certain foods like pomegranates and walnuts, has been shown to stimulate mitophagy and improve muscle health in aged animals. A human trial confirmed that urolithin A is safe and produces molecular signatures of improved mitochondrial and cellular health.28Nature Metabolism. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans Whether these molecular improvements translate into clinically meaningful benefits over years remains to be seen, but it is one of the few longevity-related compounds with both a plausible mechanism and early human safety data.
Cardiorespiratory Fitness as a Longevity Biomarker
Not everything in longevity medicine requires a prescription or a laboratory. VO2max, a measure of how much oxygen your body can use during maximum effort, has emerged as one of the strongest predictors of how long you will live. It independently predicts both all-cause mortality and disease-specific mortality.29PubMed. Survival of the fittest: VO(2)max, a key predictor of longevity? Some longevity-focused clinicians now treat VO2max the way conventional medicine treats blood pressure or cholesterol: as a number to actively manage and improve through structured exercise.
The reason VO2max is so predictive likely comes down to the fact that it reflects the integrated health of your heart, lungs, blood vessels, and skeletal muscles all at once. Improving it through consistent aerobic and high-intensity exercise addresses multiple aging-related declines simultaneously, including mitochondrial function, insulin sensitivity, inflammation, and cardiovascular reserve. For people interested in longevity who are not ready to take experimental drugs, improving cardiorespiratory fitness is the intervention with the most robust evidence behind it.
The Regulatory Frontier
One of the biggest obstacles longevity medicine faces is not scientific but regulatory. Aging is not classified as a disease by most health authorities, which means you cannot run a clinical trial with “slowing aging” as the primary outcome and expect regulatory approval. The WHO’s inclusion of an aging-associated decline code in ICD-11 and the FDA’s acceptance of the TAME trial design represent early cracks in this wall.12PubMed Central. Beyond disease treatment and prevention: From geroscience and molecular hallmarks to gerotherapeutics and precision geromedicine If TAME demonstrates that metformin can delay a composite endpoint of multiple age-related diseases, it would validate the geroscience approach in the eyes of regulators and potentially open the door for other aging-targeted therapies.
Until that happens, much of longevity medicine exists in a gray zone. Some compounds like rapamycin and metformin are prescribed off-label by longevity-focused physicians, often to affluent patients willing to pay out of pocket. Supplements like NMN and NR are sold as consumer products with minimal regulatory oversight. The science is genuinely promising in many areas, but the gap between animal data and proven human benefit remains wide for most interventions. The most honest framing of where the field stands is that the conceptual framework is strong, the biological targets are increasingly well-defined, and the treatments are mostly still in the “looks great in mice” phase of development.